

STATEMENT



18 October 2011

GSK NOT TO APPEAL COMPENSATION CLAIM MAREVAN®(warfarin) Batch Number 35222 RECALL

GSK New Zealand has reviewed the judgement made on the 26 September 2011 by District Court Judge GA Andree Wiltens on the compensation case related to costs incurred by Ian Johnson Pharmacy during the Marevan (warfarin) recall and GSK has decided not to appeal the decision.

Whilst the Marevan recall occurred in January 2010 – GSK again takes this opportunity to express its appreciation of the efforts of Medsafe, pharmacists and other healthcare professionals in helping to ensure the Marevan recall was undertaken quickly and effectively, whilst ensuring that patients needs were the primary consideration.

Ends

Media Enquiries

Lisa Maguire, Corporate Affairs GlaxoSmithKline

Office: +61 3 9721 6637

Mobile: +61 449 950 745

About MAREVAN

MAREVAN® is an anticoagulant treatment used widely in New Zealand to thin blood to help prevent blood clots.

MAREVAN is an anticoagulant belonging to a class of drug called coumarins or vitamin K antagonists. MAREVAN works by antagonising vitamin K in blood (which is needed to help blood clot), therefore inhibiting the formation of clotting factors II, VII, IX and X. It slows the clotting time of the blood. Higher levels of warfarin in the body means slower clotting time.

MAREVAN can be used for different indications (medical conditions).

For more information refer to the MAREVAN Data Sheet or the MAREVAN Consumer Medicine Information on the Medsafe website at www.medsafe.govt.nz.

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.co.nz